Novo Nordisk plans to acquire Metsera for $9 billion, challenging Pfizer's established deal.

Jin10 data reported on October 31 that Danish pharmaceutical company Novo Nordisk (NVO.N) launched a proactive acquisition of obesity drug developer Metsera on Thursday, with an offer of up to $9 billion, aiming to surpass the $7.3 billion deal reached by Pfizer (PFE.N) last month, which may trigger legal actions against the biotech company. The company proposed to acquire Metsera for $56.50 per share in cash, with an additional payment of $21.25 per share upon achieving specific milestones. Metsera stated in a separate announcement that Novo Nordisk's new offer is superior to the Pfizer proposal. According to the protocol, Pfizer currently has four days to modify the original proposal, and if Metsera ultimately determines the new offer is better, it has the right to terminate the agreement with Pfizer. Following the announcement, Metsera's stock price surged over 20%, with a cumulative rise of 78% over the past three months, while Novo Nordisk's stock price in Copenhagen fell nearly 4%.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • 1
  • Repost
  • Share
Comment
0/400
LongAndShortSuckersvip
· 3h ago
Jin10 data reported on October 31st that Danish pharmaceutical company Novo Nordisk (NVO.N) launched a proactive acquisition of obesity drug developer Metsera on Thursday, with an offer of up to $9 billion, aiming to surpass Pfizer's (PFE.N) $7.3 billion deal reached last month, which may trigger legal action against the biotechnology company. The company proposed a cash acquisition of Metsera at $56.50 per share, with an additional payment of $21.25 per share if certain milestones are met. Metsera stated in a separate announcement that Novo Nordisk's new offer is better than Pfizer's proposal. According to the protocol, Pfizer now has four days to amend its original proposal, and if Metsera ultimately determines that the new offer is superior, it has the right to terminate its agreement with Pfizer. Following the news, Metsera's stock price soared over 20%, with a cumulative increase of 78% over the past three months, while Novo Nordisk's stock price in Copenhagen fell nearly 4%.
View OriginalReply0
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)